ACH
CCCC icon

ArrowMark Colorado Holdings’s C4 Therapeutics CCCC Stock Holding History

ArrowMark Colorado Holdings’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-204,505
Closed -$391K – 299
2025
Q4 		$391K Hold
204,505
– – 0.01% 289
2025
Q3 		$454K Hold
204,505
– – 0.01% 281
2025
Q2 		$292K Sell
204,505
-1,082,207
-84% -$1.57M 0.01% 288
2025
Q1 		$2.06M Sell
1,286,712
-47,389
-4% -$141K 0.03% 226
2024
Q4 		$4.8M Buy
1,334,101
+14,617
+1% +$72.7K 0.06% 193
2024
Q3 		$7.52M Buy
1,319,484
+75,126
+6% +$452K 0.1% 158
2024
Q2 		$5.75M Sell
1,244,358
-47,581
-4% -$284K 0.07% 188
2024
Q1 		$10.6M Sell
1,291,939
-845,442
-40% -$6.55M 0.12% 142
2023
Q4 		$12.1M Sell
2,137,381
-239,425
-10% -$546K 0.13% 131
2023
Q3 		$4.42M Buy
2,376,806
+2,067,051
+667% +$6.3M 0.05% 199
2023
Q2 		$852K Sell
309,755
-6,071,125
-95% -$19.5M 0.01% 257
2023
Q1 		$20M Buy
6,380,880
+578,009
+10% +$3.4M 0.23% 88
2022
Q4 		$34.2M Buy
5,802,871
+710,896
+14% +$5.89M 0.41% 77
2022
Q3 		$44.7M Sell
5,091,975
-750,432
-13% -$7.79M 0.55% 55
2022
Q2 		$44.1M Buy
5,842,407
+3,933,384
+206% +$34.6M 0.5% 65
2022
Q1 		$46.3M Buy
1,909,023
+134,519
+8% +$3.27M 0.41% 75
2021
Q4 		$57.1M Buy
1,774,504
+259,884
+17% +$10.3M 0.46% 69
2021
Q3 		$67.7M Buy
1,514,620
+118,999
+9% +$5.1M 0.53% 59
2021
Q2 		$52.8M Buy
1,395,621
+1,144,004
+455% +$41M 0.4% 77
2021
Q1 		$9.31M Buy
251,617
+2,468
+1% +$98.2K 0.07% 200
2020
Q4 		$8.25M Buy
+249,149
New +$7.23M 0.06% 197

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

ArrowMark Colorado Holdings's CCCC Position: Q1 2026 in Review

ArrowMark Colorado Holdings sold out of C4 Therapeutics (CCCC) in Q1 2026, closing a stake of 204,505 shares — an estimated $391K sold.

ArrowMark Colorado Holdings first reported a position in CCCC in Q4 2020 and held it in 21 quarters. The position peaked at $67.7M in Q3 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • ArrowMark Colorado Holdings reported no remaining C4 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • ArrowMark Colorado Holdings sold 204,505 C4 Therapeutics shares in Q1 2026, an estimated $391K.
  • ArrowMark Colorado Holdings first reported a position in C4 Therapeutics in Q4 2020 and held it in 21 quarters.
  • ArrowMark Colorado Holdings's C4 Therapeutics position peaked at $67.7M in Q3 2021.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on ArrowMark Colorado Holdings's 13F filing for Q1 2026, filed 15 May 2026.